Theravance Bio Ord (TBPH) Stock Price, Quote & News

Company Profile

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a str...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 808 6000

Website: www.theravance.com

Address:

901 Gateway Boulevard, South San Francisco, United States

StockScanners Nov. 15 at 4:36 AM

$TBPH reached 18.20

0 · Reply

Drashkawisha Nov. 13 at 8:24 AM

$TBPH Alright team, need your help breaking this down. I'm seeing a lot of positive noise around the Q3 earnings, the big cash pile ($333M), and the stable YUPELRI revenue. Great. But the real story here is the Ampreloxetine Phase 3 (CYPRESS) data in Q1 2026, right? My question: The previous trial (0170) officially failed. But I see they showed strong data (OR 0.28) in the MSA patient subgroup. Is the current CYPRESS trial just a "clean" repeat on only that group? Is this really considered "de-risked"? And what about the competition? The incumbents (Northera/Midodrine) are carrying a Black Box Warning for supine hypertension. I read $TBPH doesn't have this safety issue. Is that the real clinical differentiation? Bottom line: If the science is strong, there's no dilution risk, and the competition is weak – why is the market sleeping on this? What am I missing? Seriously looking for the Bear Case here. Explain it to me.

0 · Reply

d_risk Nov. 12 at 10:24 PM

$TBPH - Theravance Biopharma Inc. Ordinary Shares - 10Q - Updated Risk Factors TBPH’s updated 10-Q risk factors spotlight higher US co-promotion costs and sales hurdles for YUPELRI, broader clinical trial and regulatory risks, expanded litigation and patent challenges, new FDA transparency threats, and heightened exposure to shifting healthcare laws and pricing pressures, while trimming tax and environmental risks. #Biopharma #PatentLitigation #HealthcarePricing #RegulatoryRisks #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/TBPH/10-Q/2025-11-12

0 · Reply

StockScanners Nov. 12 at 2:36 AM

$TBPH keep watch if this holds above 17.30

0 · Reply

Maximillion26 Nov. 11 at 9:30 PM

$TBPH

1 · Reply

topstockalerts Nov. 11 at 7:32 PM

$TBPH following closely 🚨

0 · Reply

demiwells Nov. 11 at 5:55 PM

$TBPH Watch the clock. NXXT may print tonight. Forefront 501,000 and UBS 43,870 added ahead of the tape

0 · Reply

ZacksResearch Nov. 11 at 4:36 PM

$TBPH beats Q3 earnings expectations — but that’s not the whole story. 💥 Revenue climbed 19%, powered by stronger collaboration income from Viatris tied to Yupelri sales — a solid sign of operational traction. Full Q3 breakdown here 👉 https://www.zacks.com/stock/news/2789369/theravances-q3-earnings-surpass-estimates-revenues-match?cid=sm-stocktwits-2-2789369-teaser-20508&ADID=SYND_STOCKTWITS_TWEET_2_2789369_TEASER_20508

0 · Reply

ZacksResearch Nov. 11 at 3:36 PM

$TBPH posts a surprise Q3 profit — what's fueling the rally? 🚀 Theravance Biopharma reported Q3 adjusted earnings of 4 cents per share, smashing the Zacks Consensus Estimate of a loss of 3 cents, driven by 19% growth in collaboration revenues with Viatris. Year to date, shares have surged 60.2% compared to the industry's 2.7% rise. Full earnings breakdown here 👉 https://www.zacks.com/stock/news/2789369/theravances-q3-earnings-surpass-estimates-revenues-match?cid=sm-stocktwits-2-2789369-body-20506&ADID=SYND_STOCKTWITS_TWEET_2_2789369_BODY_20506

0 · Reply

JarvisFlow Nov. 11 at 12:27 PM

HC Wainwright & Co. updates rating for Theravance Biopharma ( $TBPH ) to Buy, target set at 15 → 20.

0 · Reply

Theravance Biopharma, Inc. (TBPH) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 4:05 PM EST - 4 days ago

Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 29, 2025, 6:00 AM EDT - 16 days ago

Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System

Oct 27, 2025, 6:00 AM EDT - 18 days ago

Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025

Oct 16, 2025, 8:05 AM EDT - 4 weeks ago

Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy

Oct 14, 2025, 6:00 AM EDT - 4 weeks ago

Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting

Sep 2, 2025, 6:00 AM EDT - 2 months ago

Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 6:00 AM EDT - 2 months ago

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy

Aug 12, 2025, 6:52 PM EDT - 3 months ago

Theravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 3 months ago

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 28, 2025, 6:00 AM EDT - 3 months ago

Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025

Jul 23, 2025, 6:00 AM EDT - 4 months ago

Theravance Biopharma to Participate in an Upcoming Investor Conference

Jun 26, 2025, 6:00 AM EDT - 5 months ago

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA

Jun 2, 2025, 6:00 AM EDT - 5 months ago

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

GSK

May 10, 2025, 4:35 PM EDT - 6 months ago

Theravance Biopharma, Inc. (TBPH) Q1 2025 Earnings Call Transcript

May 9, 2025, 12:00 PM EDT - 6 months ago

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress

May 8, 2025, 4:05 PM EDT - 6 months ago

Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 6:00 AM EDT - 7 months ago

Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress

Apr 24, 2025, 6:00 AM EDT - 7 months ago

Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 7, 2025, 3:55 PM EDT - 7 months ago

Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting

Mar 27, 2025, 6:00 AM EDT - 8 months ago

Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology

Feb 26, 2025, 8:58 PM EST - 9 months ago

Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 9 months ago

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results

Feb 12, 2025, 6:00 AM EST - 9 months ago

Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Dec 17, 2024, 6:00 AM EST - 11 months ago

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference

Nov 12, 2024, 10:46 PM EST - 1 year ago

Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 1 year ago

Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value

Oct 24, 2024, 6:00 AM EDT - 1 year ago

Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024

Oct 18, 2024, 9:00 AM EDT - 1 year ago

Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease

Aug 5, 2024, 7:37 PM EDT - 1 year ago

Theravance Biopharma, Inc. (TBPH) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:05 PM EDT - 1 year ago

Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 22, 2024, 6:00 AM EDT - 1 year ago

Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024

May 13, 2024, 6:58 PM EDT - 1 year ago

Theravance Biopharma, Inc. (TBPH) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:05 PM EDT - 1 year ago

Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 29, 2024, 6:00 AM EDT - 1 year ago

Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024

Apr 10, 2024, 6:00 AM EDT - 1 year ago

Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024

Feb 26, 2024, 9:52 PM EST - 1 year ago

Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 4:05 PM EST - 1 year ago

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 14, 2024, 6:00 AM EST - 1 year ago

Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

Jan 5, 2024, 6:15 AM EST - 2 years ago

Theravance Biopharma's stock slides 21% after Phase 4 trial of COPD treatment fails to meet main goal

Jan 5, 2024, 6:00 AM EST - 2 years ago

Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Dec 21, 2023, 5:00 PM EST - 2 years ago

Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors

Dec 18, 2023, 6:00 AM EST - 2 years ago

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference

Nov 16, 2023, 6:00 AM EST - 2 years ago

Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System

Nov 15, 2023, 6:00 AM EST - 2 years ago

Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 13, 2023, 8:00 AM EST - 2 years ago

Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

VTRS

Nov 7, 2023, 11:23 PM EST - 2 years ago

Theravance Biopharma, Inc. (TBPH) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:28 PM EST - 2 years ago

Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 19, 2023, 6:00 AM EDT - 2 years ago

Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023

Sep 9, 2023, 11:49 AM EDT - 2 years ago

Theravance: Positive Findings Boost Ampreloxetine Development

StockScanners Nov. 15 at 4:36 AM

$TBPH reached 18.20

0 · Reply

Drashkawisha Nov. 13 at 8:24 AM

0 · Reply

d_risk Nov. 12 at 10:24 PM

0 · Reply

StockScanners Nov. 12 at 2:36 AM

$TBPH keep watch if this holds above 17.30

0 · Reply

Maximillion26 Nov. 11 at 9:30 PM

$TBPH

1 · Reply

topstockalerts Nov. 11 at 7:32 PM

$TBPH following closely 🚨

0 · Reply

demiwells Nov. 11 at 5:55 PM

$TBPH Watch the clock. NXXT may print tonight. Forefront 501,000 and UBS 43,870 added ahead of the tape

0 · Reply

ZacksResearch Nov. 11 at 4:36 PM

0 · Reply

ZacksResearch Nov. 11 at 3:36 PM

0 · Reply

JarvisFlow Nov. 11 at 12:27 PM

HC Wainwright & Co. updates rating for Theravance Biopharma ( $TBPH ) to Buy, target set at 15 → 20.

0 · Reply

G101SPM Nov. 5 at 7:20 PM

#SHOWTIME American Autonomic Society Autonomic Nervous System International Symposium (November 6-8) Scheduled to appear: $TBPH

0 · Reply

ZacksResearch Oct. 30 at 7:10 PM

$CRMD vs. $TBPH: Which small-cap biotech is your best bet? 🤔 CorMedix shines with DefenCath driving impressive growth, supported by a robust, diversified growth strategy. Meanwhile, Theravance leans heavily on its Viatris tie-up, with risks tied to a single pipeline drug. See what makes CRMD the more compelling pick 👉 https://www.zacks.com/stock/news/2781911/crmd-vs-tbph-which-small-cap-biotech-stock-is-the-better-buy?cid=sm-stocktwits-2-2781911-body-18706&ADID=SYND_STOCKTWITS_TWEET_2_2781911_BODY_18706

0 · Reply

ZacksResearch Oct. 30 at 6:10 PM

$CRMD vs. $TBPH — two small-cap biotechs, two very different growth stories 💥 CorMedix is leaning on sales traction, while Theravance is banking on its pipeline potential to drive the next leg higher. See which small-cap biotech looks like the better buy 👉 https://www.zacks.com/stock/news/2781911/crmd-vs-tbph-which-small-cap-biotech-stock-is-the-better-buy?cid=sm-stocktwits-2-2781911-teaser-18672&ADID=SYND_STOCKTWITS_TWEET_2_2781911_TEASER_18672

0 · Reply

BioTuesdays Oct. 16 at 1:20 PM

$TBPH has announced the launch of Power in the Periphery—a new disease education campaign to raise awareness and deepen scientific understanding of the pathophysiology underlying neurogenic orthostatic hypotension (nOH) associated with multiple system atrophy

0 · Reply

SweepCastApp Sep. 29 at 1:24 PM

$TBPH: Unusual Options Activity Alerted PUT flow observed 189x contracts at Strike price of $15 Exp on 12/19/2025 with Premium of $32K and showing BULLISH Sentiment

0 · Reply

RunnerSignals Sep. 12 at 11:17 PM

Analysts are throwing upgrade parties left and right! $BABA $SRAD $TBPH $GENI $TVTX all getting some analysts love today Time to see which ones actually deliver the goods! https://stocksrunner.com/news/2025-09-12-stock-upgrades-today-drive-trading-action-across-key-sectors

0 · Reply

JarvisFlow Sep. 12 at 10:00 AM

B. Riley Securities has adjusted their stance on Theravance Biopharma ( $TBPH ), setting the rating to Buy with a target price of 28.

0 · Reply

Richapeslayer_pounce Sep. 9 at 6:02 PM

$TBPH Buy here and sell at $14.25 in the next 12 to 36 hours or hold long ,can't lose either way.

0 · Reply

NVDAMillionaire Sep. 3 at 12:09 PM

$TBPH Excellent article that nails exactly where TBPH stands right now. So if you want to update your TBPH knowledge or get acquainted with TBPH, this is a must read. https://beyondspx.com/quote/TBPH/theravance-biopharma-unlocking-value-at-a-pivotal-inflection-point-nasdaq-tbph#analysis

0 · Reply

Quantumup Aug. 26 at 8:05 PM

BTIG reit'd $TBPH Buy-$25/said it conts2view CYPRESS as sig derisked by preceding P3s— $TBPH utilized an external enrollment cmte =g same clinical neuro's for both Study 0170/CYPRESS, supporting pot for +VE readthru between the two trials. $ATHE $HLUBF $HLBBF $GSK AZN BTIG said:

0 · Reply

prismmarketview Aug. 25 at 3:36 PM

(NASDAQ: $TBPH) #TheravanceBiopharma has completed enrollment in the pivotal Phase 3 CYPRESS study for ampreloxetine—targeting neurogenic orthostatic hypotension in MSA. Topline data expected Q1 2026, setting the stage for a potential accelerated NDA process. https://prismmarketview.com/theravance-biopharma-reaches-crucial-enrollment-milestone-in-phase-3-cypress-study/

0 · Reply

Thestocktraderhubzee Aug. 25 at 10:47 AM

WATCHLIST AUG 25 2025. $GIB CGI Bags Multi-Year Contract to Replace Texas Comptroller's Legacy Accounting Systems With Modern CGI Advantage Enterprise Financial Platform $GPUS Hyperscale Data To Retain All Mined Bitcoin, Expand XRP Holdings And Build AI-Optimized Data Centers Through Sentinum Subsidiary $SMX SMX And Bio-Packaging Collaboration Delivers Physical-to-Digital Authentication For Packaging To Validate Recycling Loops And Strengthen Consumer Trust In Sustainability $TBPH Theravance Biopharma Completes Enrollment In Pivotal Phase 3 Trial For Blood Pressure Disorder, Advances Phase 3 CYPRESS Study Targeting Rare Neurodegenerative Disease Affecting MSA Patients $EMR Emera Appoints Jared Green as New Chief Financial Officer Effective December 15, 2025, Succeeding Greg Blunden

0 · Reply

Market Cap	903.98M
Revenue (ttm)	64.38M
Net Income (ttm)	-56.42M
EPS (ttm)	N/A
PE Ratio	37.83
Forward PE	N/A
Profit Margin	-87.64%
Debt to Equity Ratio	0.00

Volume	474,900
Avg Vol	385,064
Day's Range	N/A - N/A
Shares Out	50.36M
Stochastic %K	65%
Beta	0.07
Analysts	Strong Sell
Price Target	$21.50